Securities Registration (section 12(g)) (8-a12g)
26 Juni 2013 - 10:59PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, DC 20549
__________________
FORM 8-A
FOR REGISTRATION OF
CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION
12(b) OR 12(g) OF THE
SECURITIES EXCHANGE
ACT OF 1934
ARCH THERAPEUTICS,
INC.
|
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
46-0524102
|
(State of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
One Broadway, 14
th
Floor
Cambridge, Massachusetts
|
|
02142
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Securities to be registered
pursuant to Section 12(b) of the Act:
Title of each class to
be so registered
|
|
Name of each exchange
on which each class is to be so registered
|
Not Applicable
|
|
Not Applicable
|
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box.
¨
|
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box.
x
|
Securities Act registration
statement file number to which this form relates: 333-178883
Securities to be registered
pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value
|
Item 1.
|
Description of Registrant’s Securities to be
Registered
.
|
The information regarding
the common stock, $0.001 par value, of Arch Therapeutics, Inc., formerly known as Almah, Inc. (the “Company”), as set
forth under the caption “Description of Securities” in the Company’s Registration Statement on Form S-1/A (File
No. 333-178883) as amended and filed with the Securities and Exchange Commission on February 24, 2012 (the “Registration
Statement”), as updated by the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission
on June 26, 2013, is incorporated herein by reference.
Exhibit Number
|
|
Description
|
3.1
|
|
Articles of Incorporation of the Company (incorporated by reference to the Company’s Registration Statement on Form S-1, filed with the SEC on January 5, 2012)
|
3.2
|
|
Certificate of Amendment to Articles of Incorporation of the Company (incorporated by reference to the Company’s Current Report on Form 8-K, filed with the SEC on June 5, 2013)
|
3.3
|
|
Amended and Restated Bylaws of the Company (incorporated by reference to the Company’s Current Report on Form 8-K, filed with the SEC on June 24, 2013)
|
SIGNATURE
Pursuant to the requirements
of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on
its behalf by the undersigned, thereto duly authorized.
|
ARCH THERAPEUTICS, INC.
|
|
|
|
|
|
|
Date: June 26, 2013
|
By:
|
/s/ Terrence W. Norchi, M.D.
|
|
|
Terrence W. Norchi, M.D.
|
|
|
President and Chief Executive Officer
|
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2024 bis Aug 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Aug 2023 bis Aug 2024
Echtzeit-Nachrichten über Arch Therapeutics Inc (QB) (OTCMarkets): 0 Nachrichtenartikel
Weitere Arch Therapeutics, Inc. News-Artikel